Engineered AAV Capsids for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors have limitations in tissue tropism and antigenicity, which restricts their therapeutic applications, necessitating the development of novel capsids with enhanced targeting capabilities to expand the gene therapy platform.
Innovation Solution
The development of recombinant adeno-associated viruses (rAAV) with AAVhu95 and AAVhu96 capsids, which are engineered to have specific amino acid modifications, allowing for improved packaging efficiency and tissue targeting, including the central nervous system and cardiac cells, by utilizing nucleic acid sequences with high identity to specific amino acid sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If AAV vectors use natural capsids from approved gene therapy products, then safety and effectiveness are ensured for current indications, but tissue tropism and antigenicity are limited, restricting therapeutic applications
Solution Approach 1:
The patent applies local quality by making specific amino acid modifications at particular positions (e.g., positions 67, 157, 412, 483) in the capsid protein sequence while maintaining the overall capsid structure. This localized modification approach allows enhancement of tissue tropism to specific targets like CNS and cardiac cells without compromising the fundamental safety and effectiveness properties of the AAV vector system
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences at specific positions in the capsid protein to create novel capsid variants (AAVhu95, AAVhu96). These parameter changes in the protein sequence directly alter tissue tropism and antigenicity while maintaining capsid structural integrity and functional reliability
2Adaptability or versatility
If AAV capsid proteins are engineered through modification to confer increased tropism to particular tissues, then tissue targeting capability is improved, but sequence and structural diversity requirements increase
Solution Approach 1:
The invention applies local quality by focusing modifications on specific hypervariable regions (HVRs) and amino acid positions in the capsid protein rather than attempting to redesign the entire capsid structure. This targeted approach to positions 67, 157, 412, and 483 enables improved tissue targeting while maintaining the established capsid architecture and reducing the complexity of sequence diversity requirements
Solution Approach 2:
The patent creates universal capsid platforms (AAVhu95, AAVhu96) that can deliver various therapeutic payloads to multiple tissue types including CNS and cardiac cells. These engineered capsids serve multiple functions - maintaining structural integrity, enabling tissue-specific targeting, and accommodating different vector genomes - thereby reducing the need for extensive sequence diversity across different applications
Data Source
AI summary
Provided herein are novel AAV capsids and recombinant AAV vectors comprising the same. In one embodiment, vectors employing a novel AAV capsid show increased transduction of a selected target tissue as compared to a prior art AAV.